Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a Healthcare company (Biotechnology) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
Intellia Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.78, Intellia Therapeutics, Inc. trades at 26.6x sales and 2.3x book value. Over the last twelve months it generated about $52M of revenue and a net loss of $460M. It runs a gross margin of 84.5%, an operating margin of -821.2% and a net margin of -805.7%. It shows return on equity of -64.7%, return on invested capital of -51.5% and a free cash flow yield of -26.1%. On the balance sheet: a debt-to-equity ratio of 0.38 and a current ratio of 6.31. Over the past 52 weeks the share price ranged from $7.95 to $18.48, with a beta of 1.82.
Intellia Therapeutics, Inc. does not currently pay a dividend.
39 Wall Street analyst ratings cover the stock: 29 Buy, 7 Hold and 3 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.